A California company has launched a new product that bundles a pregnancy test with an early dna gender collection kit. But now it's also posing ethical questions. Pink or blue, girl or boy, find out early: as early as seven weeks into the pregnancy. A company called Consumer Genetics is capitalizing on that desire with the development of a direct-to-consumer genetic testing product that reveals a baby's gender early. It's called the "pink or blue" test.

To avoid any possible contamination of male DNA giving an in-accurate result, this super-sensitive test requires no men be present while the pregnant woman pricks her finger to draw a blood sample for the lab card. Consumer genetics claims an accuracy of 95% or greater.

Dr. David Magnus, a Biomedical Ethicist at Stanford University, says accuracy rate is not his only concern. He believes consumer tests like these could lead to gender disappointment, upsetting a woman who isn't carrying the gender she desired. But he also fears it opens the door for gender selection, leading to abortions of the undesired child. Because the pink or blue test is classified as non-medical, it's not regulated by any federal medical guidelines, but you can bet ethicists will be watching.